Pharmaceutical Quality Systems - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Pharmaceutical Quality Systems
Myth versus Reality: What does Q10 implementation really mean for my company?


Pharmaceutical Technology
Volume 32, Issue 8

Myth versus Reality: What does ICH Q10 implementation really mean for my company?


Table I: ICH Q10 Gap Analysis Checklist
Myth: The elements of ICH Q10 Pharmaceutical Quality System (PQS) conflict with good manufacturing practices (GMPs) and the International Organization for Standardization's (ISO) quality management systems.


Continue


Continue
Reality: They really work together and augment each other. There are certain areas that GMPs don't specifically mention or if they are implicit, Q10 brings them out. What we have announced in the US Food and Drug Administration is an incremental approach to updating our GMPs, not a wholesale change of them. As shown in the ICH Q10 PQS model, GMPs are to be used in conjunction with the pharmaceutical quality system (PQS)....[the diagram] puts in place a way to follow GMPs and to have more holistic coverage because GMPs have always been represented as a minimal standard. ISO 9001 and Six Sigma principles are also consistent with the Q10 document. The important thing to keep in mind is that Q10 was written for pharmaceutical products. —Joseph C. Famulare, deputy director of the Center for Drug Evaluation and Research, FDA

Myth: My company outsources the bulk of its production, so we don't need a full PQS.

Reality: The sponsor has the ultimate responsibility [of the pharmaceutical product] and the agreement as to how [that product's] quality functions will be carried out and ensured will have to be worked out by the sponsor. An important passage of Q10 indicates that we will look at it as being applied to sites that manufacture products or do whatever part of that manufacturing. So Q10 is applied to sites, but holistically, if you're contracting the entire operation out, you're going to have to ensure that those quality elements are put into place, either through a whole system in your own company or through an agreement to have those systems put in place for you. —J.C.F.

Myth: Following ICH Q10 is optional.

Reality: This is in fact true. ICH Q10 is a guideline in all ICH regions. If you choose to implement Q10, you're implementing something that regulators and industry from the three ICH regions have agreed is a sound approach to a PQS. Q10 is not creating new regulation..., but it does provide guidance on ways companies can better carry out their work. —Gerald Migliaccio, vice-president of Global Quality and Environmental Health and Safety Operations, Pfizer

Myth: ICH Q10 does not relate to good laboratory practices or preclinical testing of materials.

Reality: The guideline can be applied to preclinical testing in the same way it applies to commercial manufacturing, but with an appropriate quality system approach to each stage. [Note: There are charts in the Q10 document that refer to the appropriate level of quality system implementation in the development stage.] —Karen Ginsbury, president of PCI Pharmaceutical Consulting Israel


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Pharmaceutical Technology,
Click here